Retinoic acid receptor RXR-alpha, Cell Signaling Technology, 3085

Our team performed a comprehensive review of the scientific literature to identify studies using antibodies against human retinoic acid receptor RXR-alpha, followed by extraction and evaluation of available data according to pAbmAbs rating criteria.

YCharOS conducted a systematic head-to-head comparison of ten commercially available antibodies against retinoic acid receptor RXR-alpha across multiple applications.

Antibodies were tested by WB using lysates (100 µg protein) from HCT116 WT cells and retinoic acid receptor RXR-alpha deficient HCT116 (RXRA KO) cells . These cell lines were also used for IF. In addition, antibodies were evaluated by IP using HCT116 WT cell lysate (1 mg protein). All experiments were performed according to YCharOS standard protocols (see reference).

In WB (1:1000 antibody dilution), 3085 detected a single band at the predicted size (~50 kDa) in HCT116 WT cell lysate, with no corresponding band in RXRA KO lysate.

In IP, the antibody (1µg) clearly enriched retinoic acid receptor RXR-alpha upon precipitation with no remaining protein detected in the unbound fraction. Retinoic acid receptor RXR-alpha levels in the starting material, unbound fraction, and precipitate were assessed by WB using the same antibody (1:200).

In IF, the antibody (1:100 dilution) produced a RXR-alpha-specific signal in HCT116 WT cells, co-localising with DAPI nuclear staining, with no background signal observed in RXRA KO cells.

We highly encourage other scientists to share their observations.